IDELVION albutrepenonacog alfa 3500 IU powder (and diluent) for injection

Country: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

Factor IX, Quantity: 3500 IU

Disponibbli minn:

CSL Behring Australia Pty Ltd

Għamla farmaċewtika:

Solution

Kompożizzjoni:

Excipient Ingredients:

Rotta amministrattiva:

Intravenous

Unitajiet fil-pakkett:

3500 IU

Tip ta 'preskrizzjoni:

Not scheduled. Not considered by committee

Indikazzjonijiet terapewtiċi:

IDELVION is indicated in all patients with haemophilia B for:,? Routine prophylaxis to prevent or reduce the frequency of bleeding episodes,? Control and prevention of bleeding episodes,? Control and prevention of bleeding in the perioperative setting.

Sommarju tal-prodott:

Visual Identification: Clear solution; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 3 Years; Container Temperature: Store between 2 - 25 degrees celsius; Container Closure: Neither child resistant closure nor restricted flow insert

L-istatus ta 'awtorizzazzjoni:

Registered

Data ta 'l-awtorizzazzjoni:

2020-11-19